- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Vaginal pessary containing 10mg of dinoprostone.
For the initiation of cervical ripening in patients at term (from 37 completed weeks of gestation).
For the purposes of induction of labour with dinoprostone, the onset of labour is defined as the presence of regular painful uterine contractions occurring every 3 minutes irrespective of any cervical changes.
One pessary inserted high into the posterior vaginal fornix using only small amounts of water soluble lubricants to aid insertion. The patient should be recumbent for 20 to 30 minutes after insertion.
If sufficient cervical ripening has not been achieved within 24 hours the vaginal delivery system should be removed.
An interval of at least 30 minutes is recommended for the sequential use of oxytocin following the removal of dinoprostone.
Inappropriate for use
Additional Dosage Information
A second dose of dinoprostone is not recommended as the effects of the second dose have not been studied.
Pessary for vaginal administration
After insertion the withdrawal tape may be cut ensuring there is enough tape left outside the vagina for easy removal should it be required.
The pessary should not be used or left in place when labour has started or when oxytocic drugs are being given.
Do not use in conditions where prolonged uterine contractions are inappropriate such as:
Previous Caesarean section
History of uterine surgery e.g. myomectomy
History of cervical surgery
History of cervical rupture
Uncontrolled pelvic inflammatory disease
Acute cardiac disease
Acute pulmonary disease
Acute hepatic disease
Acute renal failure
Undiagnosed vaginal bleeding during pregnancy
History of difficult or traumatic delivery
Precautions and Warnings
Assess condition of cervix before commencing treatment.
Women with the following conditions have an increased risk of developing disseminated intravascular coagulation (DIC), monitor for early signs in the immediate post partum phase:
Women aged 35 and over
Gestational age above 40 weeks
Caution is required in patients with the following;
Ruptured amniotic membranes
History of uterine hypertonia
Asthma or history of asthma
Raised intra-ocular pressure
Caution should be exercised in multiparae patients with over three previous term pregnancies.
After insertion uterine activity and the foetal condition should be monitored regularly. Any suggestion of maternal or foetal complications including adverse reactions requires the removal of the pessary.
Uterine rupture has been reported in association with dinoprostone - mainly in patients in whom its use was contraindicated (previous Caesarean section or uterine surgery).
Remove dinoprostone vaginal delivery system to terminate drug deliver when cervical ripening is judged to be complete or for the following reasons:
Evidence of maternal systemic adverse effects - nausea, vomiting, hypotension or tachycardia
Evidence of uterine hyperstimulation or hypertonic uterine contractions (with or without foetal distress), there may be a possibility of hypertonus or rupture.
Evidence of foetal distress
Onset of labour which is defined as the presence of regular painful contractions occurring every 3 minutes irrespective of cervical change. Contractions will not reduce in frequency or intensity as long as the pessary remains in situ.
Spontaneous or artificial rupture of the membranes or amniotomy
Pregnancy and Lactation
Dinoprostone should not be used during pregnancy prior to 37 completed weeks of gestation.
The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14 to 17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Dinoprostone may be excreted in colostrum and breast milk. The level and duration of dinoprostone is expected to be very limited and it is not considered necessary to hinder breastfeeding. Clinical studies have not shown any adverse effects on the breastfed new-born.
Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
Specialist advice is available from the UK Drugs in Lactation Advisory Service at https://www.midlandsmedicines.nhs.uk/content.asp?section=6&subsection=17&pageIdx=1
Effects on Ability to Drive and Operate Machinery
Uterine contractions (severe)
Amniotic fluid embolism
Foetal heart rate disorder
Rapid cervical dilation
Uterine hyper contractility with foetal bradycardia
Uterine hyper contractility without foetal bradycardia
Low Apgar score in newborn
Disseminated intravascular coagulation
Altered foetal heart rate patterns
Neonatal respiratory distress syndrome
Abnormal labour affecting foetus
Altered uterine contractions
Meconium in amniotic fluid
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Shelf Life and Storage
Store at minus 10 to 20 degrees C
Store in original container in order to protect from moisture.
Keep in storage until immediately before use.
Last Full Review Date: March 2012
British National Formulary, 63rd Edition (2012) Pharmaceutical Press, London.
Summary of Product Characteristics: Propess 10mg vaginal delivery system. Ferring Pharmaceuticals Ltd. Revised January 2017.
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.